Literature DB >> 12810704

Selective interactions between helix VIII of the human mu-opioid receptors and the C terminus of periplakin disrupt G protein activation.

Giu-Jie Feng1, Elaine Kellett, Carol A Scorer, Jonathan Wilde, Julia H White, Graeme Milligan.   

Abstract

Analysis of interactions between the C-terminal tail of the MOP-1 and MOP-1A variants of the human mu-opioid receptor with proteins derived from a human brain cDNA library resulted in identification of the actin and intermediate filament-binding protein periplakin. Mapping of this interaction indicated that the predicted fourth intracellular loop/helix VIII of the receptor interacts with the C-terminal rod and linker region of periplakin. Periplakin is widely expressed in the central nervous system of both man and rat and demonstrated an overlapping but not identical distribution with mu-opioid (MOP) receptors. Co-expression of periplakin with MOP-1 or a MOP-1-eYFP fusion construct in HEK293 cells did not interfere with agonist-mediated internalization of the receptor. When co-expressed with a MOP-1-Gi1 alpha fusion protein periplakin significantly reduced the capacity of the agonist to stimulate binding of 35S-labeled guanosine 5'-3-O-(thio)triphosphate ([35S]GTP gamma S) to the receptor-associated G protein. By contrast, periplakin did not interfere with agonist-stimulation of [35S]GTP gamma S binding to either an alpha 2A-adrenoreceptor-Gi1 alpha fusion protein or a beta2-adrenoreceptor-Gs alpha fusion protein, indicating its selectivity of function. This represents the first example of an opioid receptor-interacting protein that functions to disrupt agonist-mediated G protein activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12810704     DOI: 10.1074/jbc.M305866200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Molecular dynamics simulations reveal specific interactions of post-translational palmitoyl modifications with rhodopsin in membranes.

Authors:  Bjoern E S Olausson; Alan Grossfield; Michael C Pitman; Michael F Brown; Scott E Feller; Alexander Vogel
Journal:  J Am Chem Soc       Date:  2012-02-22       Impact factor: 15.419

2.  Platelet-activating factor receptor-mediated PI3K/AKT activation contributes to the malignant development of esophageal squamous cell carcinoma.

Authors:  J Chen; T Lan; W Zhang; L Dong; N Kang; S Zhang; M Fu; B Liu; K Liu; C Zhang; J Hou; Q Zhan
Journal:  Oncogene       Date:  2015-02-02       Impact factor: 9.867

3.  Structure of signaling-competent neurotensin receptor 1 obtained by directed evolution in Escherichia coli.

Authors:  Pascal Egloff; Matthias Hillenbrand; Christoph Klenk; Alexander Batyuk; Philipp Heine; Stefanie Balada; Karola M Schlinkmann; Daniel J Scott; Marco Schütz; Andreas Plückthun
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-22       Impact factor: 11.205

Review 4.  Molecular Pharmacology of δ-Opioid Receptors.

Authors:  Louis Gendron; Catherine M Cahill; Mark von Zastrow; Peter W Schiller; Graciela Pineyro
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

5.  Regulation of mu opioid receptor internalization by the scaffold protein RanBPM.

Authors:  Jeffery N Talbot; Donald A Skifter; Elisabetta Bianchi; Daniel T Monaghan; Myron L Toews; L Charles Murrin
Journal:  Neurosci Lett       Date:  2009-09-27       Impact factor: 3.046

Review 6.  Fine-tuning of GPCR activity by receptor-interacting proteins.

Authors:  Stefanie L Ritter; Randy A Hall
Journal:  Nat Rev Mol Cell Biol       Date:  2009-12       Impact factor: 94.444

7.  Chronic morphine treatment up-regulates mu opioid receptor binding in cells lacking filamin A.

Authors:  Irma Onoprishvili; Eric J Simon
Journal:  Brain Res       Date:  2007-08-16       Impact factor: 3.252

8.  The full-length mu-opioid receptor: a conformational study by circular dichroism in trifluoroethanol and membrane-mimetic environments.

Authors:  Isabelle Muller; Valérie Sarramégna; Marie Renault; Vincent Lafaquière; Sarra Sebai; Alain Milon; Franck Talmont
Journal:  J Membr Biol       Date:  2008-06-24       Impact factor: 1.843

9.  Periplakin gene targeting reveals a constituent of the cornified cell envelope dispensable for normal mouse development.

Authors:  Sirpa Aho; Kehua Li; Young Ryoo; Clair McGee; Akemi Ishida-Yamamoto; Jouni Uitto; John F Klement
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

10.  Direct interaction between FcgammaRI (CD64) and periplakin controls receptor endocytosis and ligand binding capacity.

Authors:  Jeffrey M Beekman; Jantine E Bakema; Jan G J van de Winkel; Jeanette H W Leusen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.